X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24521) 24521
Publication (1831) 1831
Book Review (385) 385
Book Chapter (187) 187
Book / eBook (63) 63
Newspaper Article (40) 40
Newsletter (33) 33
Conference Proceeding (25) 25
Dissertation (13) 13
Magazine Article (8) 8
Data Set (4) 4
Paper (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18010) 18010
animals (9326) 9326
index medicus (8539) 8539
male (7871) 7871
platelet aggregation - drug effects (6397) 6397
blood platelets - metabolism (6340) 6340
female (5612) 5612
blood platelets - drug effects (5253) 5253
platelet aggregation inhibitors - pharmacology (4861) 4861
hematology (4327) 4327
platelets (3615) 3615
middle aged (3595) 3595
pharmacology & pharmacy (3226) 3226
peripheral vascular disease (3194) 3194
platelet aggregation (3161) 3161
adult (3030) 3030
platelet aggregation inhibitors - therapeutic use (2905) 2905
aged (2635) 2635
rats (2605) 2605
biochemistry & molecular biology (2471) 2471
aggregation (2325) 2325
in vitro techniques (2257) 2257
activation (2254) 2254
mice (2243) 2243
blood platelets (2136) 2136
thrombosis (2079) 2079
aspirin (2045) 2045
cardiac & cardiovascular systems (1973) 1973
clopidogrel (1972) 1972
ticlopidine - analogs & derivatives (1948) 1948
dose-response relationship, drug (1922) 1922
blood platelets - physiology (1801) 1801
cell biology (1742) 1742
platelet activation (1635) 1635
inhibition (1594) 1594
platelet activation - drug effects (1556) 1556
time factors (1555) 1555
risk factors (1495) 1495
thrombin (1441) 1441
platelet-aggregation (1439) 1439
analysis (1400) 1400
rabbits (1381) 1381
adenosine diphosphate - pharmacology (1326) 1326
cells, cultured (1325) 1325
treatment outcome (1305) 1305
platelet aggregation inhibitors - administration & dosage (1297) 1297
platelet (1278) 1278
aspirin - pharmacology (1265) 1265
inflammation (1260) 1260
phosphorylation (1249) 1249
atherosclerosis (1126) 1126
thrombin - pharmacology (1126) 1126
signal transduction (1113) 1113
kinetics (1063) 1063
research (1063) 1063
proteins (1059) 1059
calcium - metabolism (1057) 1057
aspirin - therapeutic use (1038) 1038
nitric oxide (1024) 1024
expression (1021) 1021
platelet aggregation inhibitors - adverse effects (1017) 1017
myocardial-infarction (1004) 1004
ticlopidine - therapeutic use (971) 971
collagen (957) 957
fibrinogen - metabolism (953) 953
percutaneous coronary intervention (942) 942
physiological aspects (906) 906
blood platelets - enzymology (897) 897
blood (896) 896
acute coronary syndromes (883) 883
flow cytometry (878) 878
medicine, research & experimental (877) 877
collagen - pharmacology (876) 876
amino acid sequence (844) 844
article (843) 843
in-vitro (841) 841
disease (839) 839
research article (836) 836
endothelial-cells (826) 826
care and treatment (825) 825
endocrinology & metabolism (825) 825
molecular sequence data (821) 821
receptor (820) 820
health aspects (797) 797
medicine & public health (797) 797
cells (783) 783
platelet function tests (780) 780
arachidonic acid (775) 775
cardiovascular disease (771) 771
disease models, animal (767) 767
blood platelets - cytology (762) 762
medicine (756) 756
platelet glycoprotein gpiib-iiia complex - metabolism (756) 756
metabolism (753) 753
risk (749) 749
hemostasis (747) 747
protein binding (742) 742
physiology (741) 741
nitric-oxide (739) 739
cardiology (726) 726
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24264) 24264
Russian (128) 128
Japanese (106) 106
Chinese (80) 80
German (65) 65
French (37) 37
Spanish (24) 24
Polish (19) 19
Italian (12) 12
Hungarian (10) 10
Portuguese (8) 8
Swedish (6) 6
Dutch (4) 4
Korean (3) 3
Norwegian (3) 3
Ukrainian (3) 3
Czech (2) 2
Slovak (2) 2
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2009, Volume 360, Issue 4, pp. 354 - 362
The antiplatelet drug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes. This study shows that CYP polymorphisms that reduce clopidogrel... 
MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | STENT THROMBOSIS | HEALTHY-SUBJECTS | INCREASED RISK | PLATELET INHIBITION | ACUTE CORONARY SYNDROMES | PRASUGREL | ST-SEGMENT ELEVATION | INDIVIDUAL RESPONSIVENESS | ATHEROTHROMBOTIC EVENTS | Ticlopidine - pharmacology | Ticlopidine - therapeutic use | Area Under Curve | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Cardiovascular Diseases - genetics | Angioplasty, Balloon, Coronary | Ticlopidine - adverse effects | Ticlopidine - metabolism | Cardiovascular Diseases - epidemiology | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Stents | Platelet Aggregation Inhibitors - adverse effects | Genotype | Thrombosis - epidemiology | Combined Modality Therapy | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Randomized Controlled Trials as Topic | Cytochrome P-450 CYP2C19 | Acute Coronary Syndrome - therapy | Heterozygote | Thrombosis - genetics | Mutation | Usage | Genetic variation | Cytochrome P-450 | Physiological aspects | Causes of | Clopidogrel | Cardiovascular diseases | Health aspects | Risk factors | Studies | Cardiovascular disease | Heart attacks | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6
Journal Article
JAMA, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1821 - 1830
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | GASTROENTEROLOGY & HEPATOLOGY | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2010, Volume 50, Issue 2, pp. 126 - 142
Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine‐5′‐diphosphate (ADP)‐mediated platelet aggregation in vivo. These... 
prasugrel | drug interaction | pharmacokinetics | Clopidogrel | ticlopidine | metabolism | genetic polymorphism | thienopyridine | platelet aggregation | PLATELET INHIBITORY-ACTIVITY | CHROMATOGRAPHY/TANDEM MASS-SPECTROMETRY | OF-FUNCTION POLYMORPHISM | HIGH-DOSE CLOPIDOGREL | ASPIRIN-TREATED PATIENTS | CARBOXYLIC-ACID METABOLITE | PERCUTANEOUS CORONARY INTERVENTION | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | ST-SEGMENT ELEVATION | ACTIVE METABOLITE | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Ticlopidine - therapeutic use | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Piperazines - metabolism | Thiophenes - metabolism | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Polymorphism, Genetic | Acute Coronary Syndrome - drug therapy | Drug Interactions | Pyridines - metabolism | Cytochrome P-450 CYP2C19 | Ticlopidine - metabolism | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - metabolism | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Pyridines - therapeutic use | Aggregation | Blood platelets | Patient outcomes | Dosage and administration | Research | Acute coronary syndrome | Drug therapy | Pharmacokinetics | Genetic polymorphisms | Metabolites | Angina pectoris | Acute coronary syndromes | Metabolism
Journal Article